# Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Source: https://onco.cc/trials/nct07181499/  
OnCo record `nct07181499` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI is a phase 2 interventional study registered as NCT07181499 by Betta Pharmaceuticals Co., Ltd., with 28 participants planned, started 2025-09 and due to reach its primary completion in 2028-11. Interventions recorded: Befotertinib and Pemetrexed + Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07181499
- Phase: 2
- Setting: A Study Evaluating the Efficacy and Safety of Pemetrexed Combined With Platinum-Based Chemotherapy Followed by Befotertinib in Patients With Non-Small Cell Lung Cancer After Third-Generation EGFR TKI Resistance
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT07181499: https://clinicaltrials.gov/study/NCT07181499

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Befotertinib](https://onco.cc/drugs/befotertinib/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)

---
JSON: https://onco.cc/api/v1/entities/nct07181499.json